Please login to the form below

How scenario testing helped assess demand for a brand launch in the fragmented NSCLC market


Our client was developing a new drug aimed at first line NSCLC patients. Ahead of its launch they wanted to assess likely uptake in an already fragmented market space led by established 1st generation tyrosine kinase inhibitors (TKIs). There were several scenarios that the client wanted to test, including impact of launch order and the impact of future 3rd generation TKIs on the drug’s market potential. The research was complicated by the fact that both the clients (and likely key future competitors’), profile was as yet unknown – the research therefore needed to assess likely share while taking account of multiple moving parts...

Read the full case study: 
https://bit.ly/2GG0jh2


29th March 2018

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Rare diseases and orphan drugs: Our experience and expertise

Research Partnership
Conducting research for publication video

Research Partnership
Conference research case study
How conference research was used to gauge reactions to new clinical data and measure the impact of a company’s presence at a leading industry event
Research Partnership
Portfolio analysis: Using market research to master communications across a therapeutic category

Research Partnership
EphMRA round up 2018
EU Directors Angela Duffy, Richard Head and Dan coffin attended the EphMRA annual conference in Basel.
Research Partnership
Patients’willingness to pay
Considerations when developing an appropriate pricing strategy in self-pay markets
Research Partnership